Publications
2022
Scholarly publications
Bagheri, M., van Nostrum, C. F., Kok, R. J., Storm, G., Hennink, W. E., & Heger, M. (2022). Utility of Intravenous Curcumin Nanodelivery Systems for Improving In Vivo Pharmacokinetics and Anticancer Pharmacodynamics. Molecular Pharmaceutics, 19(9), 3057–3074. https://doi.org/10.1021/acs.molpharmaceut.2c00455
2021
Scholarly publications
Levey, R. E., Coulter, F. B., Scheiner, K. C., Deotti, S., Robinson, S. T., McDonough, L., Nguyen, T. T., Steendam, R., Canney, M., Wylie, R., Burke, L. P., Dolan, E. B., Dockery, P., Kelly, H. M., Ghersi, G., Hennink, W. E., Kok, R. J., O'Cearbhaill, E., & Duffy, G. P. (2021). Assessing the Effects of VEGF Releasing Microspheres on the Angiogenic and Foreign Body Response to a 3D Printed Silicone-Based Macroencapsulation Device. Pharmaceutics, 13(12), 1-16. [2077]. https://doi.org/10.3390/pharmaceutics13122077
Scheiner, K. C., Maas-Bakker, R. F., van Steenbergen, M. J., Schwendeman, S. P., Hennink, W. E., & Kok, R. J. (2021). Post-loading of proangiogenic growth factors in PLGA microspheres. European Journal of Pharmaceutics and Biopharmaceutics, 158, 1-10. https://doi.org/10.1016/j.ejpb.2020.10.022
Bagheri, M., Fens, M. H., Kleijn, T. G., Capomaccio, R. B., Mehn, D., Krawczyk, P. M., Scutigliani, E. M., Gurinov, A., Baldus, M., van Kronenburg, N. C. H., Kok, R. J., Heger, M., van Nostrum, C. F., & Hennink, W. E. (2021). In Vitro and In Vivo Studies on HPMA-Based Polymeric Micelles Loaded with Curcumin. Molecular Pharmaceutics, 18(3), 1247-1263. https://doi.org/10.1021/acs.molpharmaceut.0c01114
2020
Scholarly publications
Liu, Y., Fens, M. H. A. M., Capomaccio, R. B., Mehn, D., Scrivano, L., Kok, R. J., Oliveira, S., Hennink, W. E., & van Nostrum, C. F. (2020). Correlation between in vitro stability and pharmacokinetics of poly(ε-caprolactone)-based micelles loaded with a photosensitizer. Journal of controlled release : official journal of the Controlled Release Society, 328, 942-951. https://doi.org/10.1016/j.jconrel.2020.10.040
Shi, H., van Steenbergen, M. J., Lou, B., Liu, Y., Hennink, W. E., & Kok, R. J. (2020). Folate decorated polymeric micelles for targeted delivery of the kinase inhibitor dactolisib to cancer cells. International Journal of Pharmaceutics, 582, [119305]. https://doi.org/10.1016/j.ijpharm.2020.119305
Liu, Y., Fens, M. H. A. M., Lou, B., van Kronenburg, N. C. H., Maas-Bakker, R. F. M., Kok, R. J., Oliveira, S., Hennink, W. E., & van Nostrum, C. F. (2020). π-π-Stacked Poly(ε-caprolactone)-b-poly(ethylene glycol) Micelles Loaded with a Photosensitizer for Photodynamic Therapy. Pharmaceutics, 12(4), [338]. https://doi.org/10.3390/pharmaceutics12040338
Scheiner, K. C., Coulter, F., Maas-Bakker, R. F., Ghersi, G., Nguyen, T. T., Steendam, R., Duffy, G. P., Hennink, W. E., O'Cearbhaill, E. D., & Kok, R. J. (2020). Vascular Endothelial Growth Factor-Releasing Microspheres Based on Poly(ε-Caprolactone-PEG-ε-Caprolactone)-b-Poly(L-Lactide) Multiblock Copolymers Incorporated in a Three-Dimensional Printed Poly(Dimethylsiloxane) Cell Macroencapsulation Device. Journal of Pharmaceutical Sciences, 109(1), 863-870. https://doi.org/10.1016/j.xphs.2019.10.028
2019
Scholarly publications
Leneweit, G., Miranda, B. S., de Matos, M. B. C., Beztsinna, N., Heyder, C., Dührkop, C., Nirschl, H., Ekdahl, K. N., Nilsson, B., Mastrobattista, E., & Kok, R. J. (2019). Colloidal formulation of mistletoe extracts in a pharmaceutical flow process for targeted cancer therapy. Phytomedicine, 61(Supplement 1). https://doi.org/10.1016/j.phymed.2019.09.118
de Matos, M. B. C., Deckers, R., van Elburg, B., Lajoinie, G., de Miranda, B. S., Versluis, M., Schiffelers, R., & Kok, R. J. (2019). Ultrasound-Sensitive Liposomes for Triggered Macromolecular Drug Delivery: Formulation and In Vitro Characterization. Frontiers in Pharmacology, 10, 1463. https://doi.org/10.3389/fphar.2019.01463
Scheiner, K. C., Maas-Bakker, R. F., Nguyen, T. T., Duarte, A. M., Hendriks, G., Sequeira, L., Duffy, G. P., Steendam, R., Hennink, W. E., & Kok, R. J. (2019). Sustained Release of Vascular Endothelial Growth Factor from Poly(ε-caprolactone-PEG-ε-caprolactone)‑b‑Poly(L‑lactide) Multiblock Copolymer Microspheres. ACS Omega, 4(7), 11481-11492. https://doi.org/10.1021/acsomega.9b01272
Shi, H., Lou, B., van Steenbergen, M. J., Sijbrandi, N. J., Hennink, W. E., & Kok, R. J. (2019). Polymeric Micelles Employing Platinum(II) Linker for the Delivery of the Kinase Inhibitor Dactolisib. Particle and Particle Systems Characterization, 36(8), [1900236]. https://doi.org/10.1002/ppsc.201900236
den Hoedt, C. H., van Gelder, M. K., Grooteman, M. P., Nubé, M. J., Blankestijn, P. J., Goldschmeding, R., Kok, R. J., Bots, M. L., van den Dorpel, M. A., & Gerritsen, K. G. F. (2019). Connective Tissue Growth Factor Is Related to All-cause Mortality in Hemodialysis Patients and Is Lowered by On-line Hemodiafiltration: Results from the Convective Transport Study. Toxins, 11(5), [268]. https://doi.org/10.3390/toxins11050268
Sadeghi, N., Kok, R., Bos, C., Zandvliet, M., Geerts, W., Storm, G., Moonen, C. T. W., Lammers, T., & Deckers, R. (2019). Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy in vitro. Nanotechnology, 30(26). https://doi.org/10.1088/1361-6528/ab0ce6
de Matos, M., Miranda, B. S., Rizky Nuari, Y., Storm, G., Leneweit, G., Schiffelers, R. M., & Kok, R. J. (2019). Liposomes with asymmetric bilayers produced from inverse emulsions for nucleic acid delivery. Journal of Drug Targeting, 27(5-6), 681-689. https://doi.org/10.1080/1061186X.2019.1579819
Shi, H., Leonhard, W. N., Sijbrandi, N. J., van Steenbergen, M. J., Fens, M. H. A. M., van de Dikkenberg, J. B., Toraño, J. S., Peters, D. J. M., Hennink, W. E., & Kok, R. J. (2019). Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys. Journal of controlled release : official journal of the Controlled Release Society, 293, 113-125. https://doi.org/10.1016/j.jconrel.2018.11.019
Buwalda, S., Nottelet, B., Bethry, A., Kok, R. J., Sijbrandi, N., & Coudane, J. (2019). Reversibly core-crosslinked PEG-P(HPMA) micelles: Platinum coordination chemistry for competitive-ligand-regulated drug delivery. Journal of Colloid and Interface Science, 535, 505-515. https://doi.org/10.1016/j.jcis.2018.10.001
2018
Scholarly publications
de Matos, M. B. C., Beztsinna, N., Heyder, C., Fens, M. H. A. M., Mastrobattista, E., Schiffelers, R. M., Leneweit, G., & Kok, R. J. (2018). Thermosensitive liposomes for triggered release of cytotoxic proteins. European Journal of Pharmaceutics and Biopharmaceutics, 132, 211-221. https://doi.org/10.1016/j.ejpb.2018.09.010
Beztsinna, N., de Matos, M. B. C., Walther, J., Heyder, C., Hildebrandt, E., Leneweit, G., Mastrobattista, E., & Kok, R. J. (2018). Quantitative analysis of receptor-mediated uptake and pro-apoptotic activity of mistletoe lectin-1 by high content imaging. Scientific Reports, 8(1), [2768]. https://doi.org/10.1038/s41598-018-20915-y
Hildebrandt, E., Nirschl, H., Kok, R. J., & Leneweit, G. (2018). Adsorption of phospholipids at oil/water interfaces during emulsification is controlled by stress relaxation and diffusion. Soft Matter, 14(19), 3730-3737. https://doi.org/10.1039/c8sm00005k
Gholizadeh, S., Dolman, E. M., Wieriks, R., Sparidans, R. W., Hennink, W. E., & Kok, R. J. (2018). Anti-GD2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells. Pharmaceutical Research, 35(4), [85]. https://doi.org/10.1007/s11095-018-2373-x
Nemes, Z., Takács-Novák, K., Völgyi, G., Valko, K., Béni, S., Horváth, Z., Szokol, B., Breza, N., Dobos, J., Szántai-Kis, C., Illyés, E., Boros, S., Kok, R. J., & Őrfi, L. (2018). Synthesis and characterization of amino acid substituted sunitinib analogues for the treatment of AML. Bioorganic and Medicinal Chemistry Letters, 28(14), 2391-2398. https://doi.org/10.1016/j.bmcl.2018.06.026
Gholizadeh Soltani, S., Kamps, J. A. A. M., Hennink, W. E., & Kok, R. J. (2018). PLGA-PEG nanoparticles for targeted delivery of the mTOR/PI3kinase inhibitor dactolisib to inflamed endothelium. International Journal of Pharmaceutics, 548(2), 747-758. https://doi.org/10.1016/j.ijpharm.2017.10.032
Sadeghi, N., Deckers, R., Ozbakir, B., Akhtar, S., Kok, R. J., Lammers, T., & Storm, G. (2018). Influence of cholesterol inclusion on the doxorubicin release characteristics of lysolipid-based thermosensitive liposomes. International Journal of Pharmaceutics, 548(2), 778-782. https://doi.org/10.1016/j.ijpharm.2017.11.002
Sommerling, J-H., Carreira de Matos, M., Hildebrandt, E., Dessy, A., Kok, R. J., Nirschl, H., & Leneweit, G. (2018). Instability Mechanisms of Water-in-Oil Nanoemulsions with Phospholipids: Temporal and Morphological Structures. Langmuir, 34(2), 572-584. https://doi.org/10.1021/acs.langmuir.7b02852
Fülöp, T., Nemes, R., Mészáros, T., Urbanics, R., Kok, R. J., Jackman, J. A., Storm, G., & Szebeni, J. (2018). Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: Correlation with physicochemical features and clinical information. Journal of Controlled Release, 270, 268-274. https://doi.org/10.1016/j.jconrel.2017.11.043
Gholizadeh Soltani, S., Visweswaran, G. R. R., Storm, G., Hennink, W. E., Kamps, J. A. A. M., & Kok, R. J. (2018). E-selectin targeted immunoliposomes for rapamycin delivery to activated endothelial cells. International Journal of Pharmaceutics, 548(2), 759-770. https://doi.org/10.1016/j.ijpharm.2017.10.027
Chen, W., di Carlo, C., Devery, D., McGrath, D. J., McHugh, P. E., Kleinsteinberg, K., Jockenhoevel, S., Hennink, W. E., & Kok, R. J. (2018). Fabrication and characterization of gefitinib-releasing polyurethane foam as a coating for drug-eluting stent in the treatment of bronchotracheal cancer. International Journal of Pharmaceutics, 548(2), 803-811. https://doi.org/10.1016/j.ijpharm.2017.10.026
2017
Scholarly publications
Chen, W., Clauser, J., Thiebes, A. L., McGrath, D. J., Kelly, N., van Steenbergen, M. J., Jockenhoevel, S., Steinseifer, U., McHugh, P. E., Hennink, W. E., & Kok, R. J. (2017). Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating. European Journal of Pharmaceutical Sciences, 103, 94-103. https://doi.org/10.1016/j.ejps.2017.02.002
Chen, W., Palazzo, A., Hennink, W. E., & Kok, R. J. (2017). Effect of particle size on drug loading and release kinetics of gefitinib-loaded PLGA microspheres. Molecular Pharmaceutics, 14(2), 459-467. https://doi.org/10.1021/acs.molpharmaceut.6b00896
Thiebes, A. L., Kelly, N., Sweeney, C. A., McGrath, D. J., Clauser, J., Kurtenbach, K., Gesche, V. N., Chen, W., Kok, R. J., Steinseifer, U., Bruzzi, M., O’Brien, B. J., McHugh, P. E., Jockenhoevel, S., & Cornelissen, C. G. (2017). PulmoStent: In Vitro to In Vivo Evaluation of a Tissue Engineered Endobronchial Stent. Annals of Biomedical Engineering, 45(4), 873-883. https://doi.org/10.1007/s10439-016-1737-9
2016
Scholarly publications
Alaarg, A., Perez Medina, C., Tang, J., Fay, F., Zhao, Y., Sanchez-Gaytan, B., Reiner, T., Fayad, Z. A., Kok, R. J., Metselaar, J. M., Mulder, W. J., & Storm, G. (2016). Design and development of nanomedicines to treat atherosclerosis: A cross platform head-to-head theranostic study. Molecular Imaging and Biology, 18(Supplement 2), 311-312. [2500142]. https://doi.org/10.1007/s11307-016-1031-0
Alaarg, A., Jordan, N. Y., Verhoef, J. J. F., Metselaar, J. M., Storm, G., & Kok, R. J. (2016). Docosahexaenoic acid liposomes for targeting chronic inflammatory diseases and cancer: An in vitro assessment. International Journal of Nanomedicine, 11, 5027-5040. https://doi.org/10.2147/IJN.S115995
Chen, W., Clauser, J., Thiebes, A. L., McGrath, D. J., McHugh, P. E., Steinseifer, U., Jockenhoevel, S., Hennink, W. E., & Kok, R. J. (2016). Selection and fabrication of a non-woven polycarbonate urethane cover for a tissue engineered airway stent. International Journal of Pharmaceutics, 514(1), 255-262. https://doi.org/10.1016/j.ijpharm.2016.06.047
Janssen, M. J., Arcolino, F. O., Schoor, P., Kok, R. J., & Mastrobattista, E. (2016). Gene based therapies for kidney regeneration. European Journal of Pharmacology, 790, 99-108. https://doi.org/10.1016/j.ejphar.2016.07.037
Gerritsen, K. G., Falke, L. L., van Vuuren, S. H., Leeuwis, J. W., Broekhuizen, R., Nguyen, T. Q., de Borst, G. J., Nathoe, H. M., Verhaar, M. C., Kok, R. J., Goldschmeding, R., Visseren, F. L., & Moll, F. L. (2016). Plasma CTGF is independently related to an increased risk of cardiovascular events and mortality in patients with atherosclerotic disease: the SMART study. Growth Factors, 34(3-4), 149-158. https://doi.org/10.1080/08977194.2016.1210142
Gerritsen, K. G. F., Bovenschen, N., Nguyen, T. Q., Sprengers, D., Koeners, M. P., van Koppen, A. N., Joles, J. A., Goldschmeding, R., & Kok, R. J. (Accepted/In press). Rapid hepatic clearance of full length CCN-2/CTGF: a putative role for LRP1-mediated endocytosis. Journal of Cell Communication and Signaling, 1-9. https://doi.org/10.1007/s12079-016-0354-6
Ramazani, F., van Nostrum, C. F., Storm, G., Kiessling, F., Lammers, T., Hennink, W. E., & Kok, R. J. (2016). Locoregional cancer therapy using polymer-based drug depots. Drug Discovery Today, 21(4), 640-647. https://doi.org/10.1016/j.drudis.2016.02.014
Shirangi, M., Najafi, M., Rijkers, D. T. S., Kok, R. J., Hennink, W. E., & van Nostrum, C. F. (2016). Inhibition of Octreotide Acylation Inside PLGA Microspheres by Derivatization of the Amines of the Peptide with a Self-Immolative Protecting Group. Bioconjugate Chemistry, 576-585. https://doi.org/10.1021/acs.bioconjchem.5b00598
Ramazani, F., Chen, W., van Nostrum, C. F., Storm, G., Kiessling, F., Lammers, T., Hennink, W. E., & Kok, R. J. (2016). Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges. International Journal of Pharmaceutics, 499(1-2), 358-367. https://doi.org/10.1016/j.ijpharm.2016.01.020
2015
Scholarly publications
Visweswaran, G. R. R., Gholizadeh, S., Ruiters, M. H. J., Molema, G., Kok, R. J., & Kamps, J. A. A. M. (2015). Targeting Rapamycin to Podocytes Using a Vascular Cell Adhesion Molecule-1 (VCAM-1)-Harnessed SAINT-Based Lipid Carrier System. PLoS One, 10(9), e0138870. https://doi.org/10.1371/journal.pone.0138870
Gerritsen, K. G. F., Leeuwis, J. W., Koeners, M. P., Bakker, S. J. L., van Oeveren, W., Aten, J., Tarnow, L., Rossing, P., Wetzels, J. F. M., Joles, J. A., Kok, R. J., Goldschmeding, R., & Nguyen, T. Q. (2015). Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. Diabetes Care, 2015, [539787]. https://doi.org/10.1155/2015/539787
Dolman, M. E. M., Poon, E., Ebus, M. E., Den Hartog, I. J. M., Van Noesel, C. J. M., Jamin, Y., Hallsworth, A., Robinson, S. P., Petrie, K., Sparidans, R. W., Kok, R. J., Versteeg, R., Caron, H. N., Chesler, L., & Molenaar, J. J. (2015). Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. Clinical Cancer Research, 21(22), 5100-5109. https://doi.org/10.1158/1078-0432.CCR-15-0313
Chen, W., Habraken, T. C. J., Hennink, W. E., & Kok, R. J. (2015). Polymer-Free Drug-Eluting Stents: An Overview of Coating Strategies and Comparison with Polymer-Coated Drug-Eluting Stents. Bioconjugate Chemistry, 26(7), 1277-1288. https://doi.org/10.1021/acs.bioconjchem.5b00192
Ramazani, F., Hiemstra, C., Steendam, R., Kazazi-Hyseni, F., Van Nostrum, C. F., Storm, G., Kiessling, F., Lammers, T., Hennink, W. E., & Kok, R. J. (2015). Sunitinib microspheres based on [PDLLA-PEG-PDLLA]-b-PLLA multi-block copolymers for ocular drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 95, 368-377. https://doi.org/10.1016/j.ejpb.2015.02.011
Kazazi-Hyseni, F., Van Vuuren, S. H., Van Der Giezen, D. M., Pieters, E. H., Ramazani, F., Rodriguez, S., Veldhuis, G. J., Goldschmeding, R., Van Nostrum, C. F., Hennink, W. E., & Kok, R. J. (2015). Release and pharmacokinetics of near-infrared labeled albumin from monodisperse poly(D,L-lactic-co-hydroxymethyl glycolic acid) microspheres after subcapsular renal injection. Acta Biomaterialia, 22, 141-154. https://doi.org/10.1016/j.actbio.2015.04.030
Falke, L. L., Gholizadeh Soltani, S., Goldschmeding, R., Kok, R. J., & Nguyen, T. Q. (2015). Diverse origins of the myofibroblast-implications for kidney fibrosis. Nature Reviews. Nephrology, 11(4), 233-244. https://doi.org/10.1038/nrneph2014246
Falke, L. L., van Vuuren, S. H., Kazazi-Hyseni, F., Ramazani, F., Nguyen, T. Q., Veldhuis, G. J., Maarseveen, E. M., Zandstra, J., Zuidema, J., Duque, L. F., Steendam, R., Popa, E. R., Kok, R. J., & Goldschmeding, R. (2015). Local therapeutic efficacy with reduced systemic side effects by rapamycin-loaded subcapsular microspheres. Biomaterials, 42, 151-60. https://doi.org/10.1016/j.biomaterials.2014.11.042
Ramazani, F., Chen, W., Van Nostrum, C. F., Storm, G., Kiessling, F., Lammers, T., Hennink, W. E., & Kok, R. J. (2015). Formulation and characterization of microspheres loaded with imatinib for sustained delivery. International Journal of Pharmaceutics, 482(1-2), 123-130. https://doi.org/10.1016/j.ijpharm.2015.01.043
Kazazi-Hyseni, F., Zandstra, J., Popa, E. R., Goldschmeding, R., Lathuile, A. A. R., Veldhuis, G. J., Van Nostrum, C. F., Hennink, W. E., & Kok, R. J. (2015). Biocompatibility of poly(d,l-lactic-co-hydroxymethyl glycolic acid) microspheres after subcutaneous and subcapsular renal injection. International Journal of Pharmaceutics, 482(1-2), 99-109. https://doi.org/10.1016/j.ijpharm.2014.12.014
2014
Scholarly publications
Stokman, G., Qin, Y., Booij, T. H., Ramaiahgari, S., Lacombe, M., Dolman, M. E. M., Van Dorenmalen, K. M. A., Teske, G. J. D., Florquin, S., Schwede, F., Van De Water, B., Kok, R. J., & Price, L. S. (2014). Epac-rap signaling reduces oxidative stress in the tubular epithelium. Journal of the American Society of Nephrology, 25(7), 1474-1485. https://doi.org/10.1681/ASN.2013070679
Dézsi, L., Fülöp, T., Mészáros, T., Szénási, G., Urbanics, R., Vázsonyi, C., Őrfi, E., Rosivall, L., Nemes, R., Kok, R. J., Metselaar, J. M., Storm, G., & Szebeni, J. (2014). Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses. Journal of Controlled Release, 195, 2-10. https://doi.org/10.1016/j.jconrel.2014.08.009
Heukers, R., Altintas, I., Raghoenath, S., De Zan, E., Pepermans, R., Roovers, R. C., Haselberg, R., Hennink, W. E., Schiffelers, R. M., Kok, R. J., & Van Bergen en Henegouwen, P. M. P. (2014). Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles. Biomaterials, 35(1), 601-610. https://doi.org/10.1016/j.biomaterials.2013.10.001
Kazazi-Hyseni, F., Landin, M., Lathuile, A., Veldhuis, G. J., Rahimian, S., Hennink, W. E., Kok, R. J., & van Nostrum, C. F. (2014). Computer Modeling Assisted Design of Monodisperse PLGA Microspheres with Controlled Porosity Affords Zero Order Release of an Encapsulated Macromolecule for 3 Months. Pharmaceutical Research, 31(10), 2844-2856. https://doi.org/10.1007/s11095-014-1381-8
Petit, A., Sandker, M., Müller, B., Meyboom, R., van Midwoud, P., Bruin, P., Redout, E. M., Versluijs-Helder, M., van der Lest, C. H. A., Buwalda, S. J., de Leede, L. G. J., Vermonden, T., Kok, R. J., Weinans, H., & Hennink, W. E. (2014). Release behavior and intra-articular biocompatibility of celecoxib-loaded acetyl-capped PCLA-PEG-PCLA thermogels. Biomaterials, 35(27), 7919-7928. https://doi.org/10.1016/j.biomaterials.2014.05.064
2013
Scholarly publications
van der Meel, R., Oliveira, S., Altintas, I., Heukers, R., Pieters, E. H. E., van Bergen en Henegouwen, P. M. P., Storm, G., Hennink, W., Kok, R. J., & Schiffelers, R. M. (2013). Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways. Molecular Pharmaceutics, 10(10), 3717-27. https://doi.org/10.1021/mp400212v
Oliveira, S., Heukers, R., Sornkom, J., Kok, R. J., & van Bergen En Henegouwen, P. M. P. (2013). Targeting tumors with nanobodies for cancer imaging and therapy. Journal of Controlled Release, 172(3), 607-17. https://doi.org/10.1016/j.jconrel.2013.08.298
Altintas, I., Heukers, R., van der Meel, R., Lacombe, M., Amidi, M., van Bergen en Henegouwen, P. M. P., Hennink, W. E., Schiffelers, R. M., & Kok, R. J. (2013). Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. Journal of Controlled Release, 165(2), 110-118. http://www.ncbi.nlm.nih.gov/pubmed/23159529
van der Meel, R., Vehmeijer, L. J., Kok, R. J., Storm, G., & van Gaal, E. V. B. (2013). Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status. Advanced Drug Delivery Reviews, 65(10), 1284-98.
Akhter, S., Ahmad, I., Ahmad, M. Z., Ramazani, F., Singh, A., Rahman, Z., Ahmad, F. J., Storm, G., & Kok, R. J. (2013). Nanomedicines as cancer therapeutics: current status. Curr Cancer Drug Targets, 13(4), 362-78.
Other output
Houthoff, H. J., van Dongen, A. A. M. S., Kok, R. J., Waalboer, D. C. J., Buwalda, S. J., & Sijbrandi, N. J. (2013). Method for preparing cell targeting conjugates, and the complexes obtained. (Patent No. WO/2013/103301).
2012
Scholarly publications
Dolman, M., Harmsen, S., Pieters, E. H. E., Sparidans, R. W., Lacombe, M., Szokol, B., Orfi, L., Kéri, G., Storm, G., Hennink, W. E., & Kok, R. J. (2012). Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells. International Journal of Nanomedicine, 7, 417-433. https://doi.org/10.2147/IJN.S26485
Dolman, E., van Dorenmalen, K. M. A., Pieters, E. H. E., Sparidans, R. W., Lacombe, M., Szokol, B., Orfi, L., Kéri, G., Bovenschen, N., Storm, G., Hennink, W. E., & Kok, R. J. (2012). Dendrimer-based macromolecular conjugate for the kidney-directed delivery of a multitargeted sunitinib analogue. Macromolecular Bioscience, 12(1), 93-103. https://doi.org/10.1002/mabi.201100277
Van Der Meel, R., Oliveira, S., Altintas, I., Haselberg, R., Roovers, R. C., Van Bergen en Henegouwen, P. M. P., Hennink, W. E., Storm, G., Schiffelers, R. M., & Kok, R. J. (2012). Tumor-targeted nanobullets for anti-cancer combination therapy. European Journal of Cancer, 48, 38. https://doi.org/10.1016/S0959-8049(12)71919-6
Ghassemi, A. H., Van Steenbergen, M. J., Barendregt, A., Talsma, H., Kok, R. J., Van Nostrum, C. F., Crommelin, D. J. A., & Hennink, W. E. (2012). Controlled release of octreotide and assessment of peptide acylation from poly(D,L-lactide-co-hydroxymethyl glycolide) compared to PLGA microspheres. Pharmaceutical Research, 29(1), 110-120. https://doi.org/10.1007/s11095-011-0517-3
Akhter, S., Ahmad, M. Z., Ahmad, F. J., Storm, G., & Kok, R. J. (2012). Gold nanoparticles in theranostic oncology: current state-of-the-art. Expert Opinion on Drug Delivery, 9(10), 1225-43.
Gerritsen, K. G., Abrahams, A. C., Peters, H. P., Nguyen, T. Q., Koeners, M. P., Den Hoedt, C. H., Dendooven, A., Van Den Dorpel, M. A., Blankestijn, P. J., Wetzels, J. F., Joles, J. A., Goldschmeding, R., & Kok, R. J. (2012). Effect of GFR on plasma N-terminal Connective Tissue Growth Factor (CTGF) concentrations. American Journal of Kidney Diseases, 59(5), 619-627. https://doi.org/10.1053/j.ajkd.2011.12.019
Altintas, I., Kok, R. J., & Schiffelers, R. M. (2012). Targeting epidermal growth factor receptor in tumors: from conventional monoclonal antibodies via heavy chain-only antibodies to nanobodies. European Journal of Pharmaceutical Sciences, 45(4), 399-407.
Dolman, M. E. M., van Dorenmalen, K. M. A., Pieters, E. H. E., Lacombe, M., Pato, J., Storm, G., Hennink, W. E., & Kok, R. J. (2012). Imatinib-ULS-lysozyme: a proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases. Journal of Controlled Release, 157(3), 461-8.
van der Meel, R., Oliveira, S., Altintas, I., Haselberg, R., van der Veeken, J., Roovers, R. C., van Bergen en Henegouwen, P. M. P., Storm, G., Hennink, W. E., Schiffelers, R. M., & Kok, R. J. (2012). Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment. Journal of Controlled Release, 159(2), 281-9. http://www.ncbi.nlm.nih.gov/pubmed/22227023
de Graaf, A. J., Azevedo Próspero dos Santos, I. I., Pieters, E. H. E., Rijkers, D. T. S., van Nostrum, C. F., Vermonden, T., Kok, R. J., Hennink, W. E., & Mastrobattista, E. (2012). A micelle-shedding thermosensitive hydrogel as sustained release formulation. Journal of Controlled Release, 162, 582-590.
Harmsen, S., & Kok, R. J. (2012). Kinase inhibitor conjugates. Current Pharmaceutical Design, 18(20), 2891-900.
Dolman, M. E. M., van Dorenmalen, K. M. A., Pieters, E. H. E., Sparidans, R. W., Lacombe, M., Szokol, B., Örfi, L., Kéri, G., Bovenschen, N., Storm, G., Hennink, W. E., & Kok, R. J. (2012). Dendrimer-Based Macromolecular Conjugate for the Kidney-Directed Delivery of a Multitargeted Sunitinib Analoguw. Macromolecular Bioscience, 12(1), 93-103. http://www.ncbi.nlm.nih.gov/pubmed/21998092
Altintas, I., Heukers, R., van der Meel, R., Lacombe, M., Amidi, M., van Bergen en Henegouwen, P. M. P., Hennink, W. E., Schiffelers, R. M., & Kok, R. J. (2012). Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells. Cell Biology International, 165(2), 110-118. https://doi.org/10.1016/j.jconrel.2012.11.007
Poosti, F., Yazdani, S., Dolman, M. E. M., Kok, R. J., Chen, C., Ding, G., Lacombe, M., Prakash, J., Born, J., Hillebrands, J. L., van Goor, H., & de Borst, M. H. (2012). Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection. European Journal of Pharmacology, 694(1-3), 111-9.
2011
Scholarly publications
D'Aurizio, E., Sozio, P., Cerasa, L. S., Vacca, M., Brunetti, L., Orlando, G., Chiavaroli, A., Kok, R. J., Hennink, W. E., & Di Stefano, A. (2011). Biodegradable microspheres loaded with an anti-Parkinson prodrug: An in vivo pharmacokinetic study. Molecular Pharmaceutics, 8(6), 2408-2415. https://doi.org/10.1021/mp200337h
Harmsen, S., Dolman, M. E. M., Nemes, Z., Lacombe, M., Szokol, B., Pato, J., Keri, G., Orfi, L., Storm, G., Hennink, W. E., & Kok, R. J. (2011). Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate. Bioconjugate Chemistry, 22(4), 540-5.
van Gaal, E. V. B., van Eijk, R., Oosting, R. S., Kok, R. J., Hennink, W. E., Crommelin, D. J. A., & Mastrobattista, E. (2011). How to screen non-viral gene delivery systems in vitro? Journal of Controlled Release, 154(3), 218-32.
Dendooven, A., Gerritsen, K. G. F., Nguyen, T. Q., Kok, R. J., & Goldschmeding, R. (2011). Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers, 16(4), 289-301. http://www.ncbi.nlm.nih.gov/pubmed/21595567
van der Meel, R., Symons, M. H., Kudernatsch, R., Kok, R. J., Schiffelers, R. M., Storm, G., Gallagher, W. M., & Byrne, A. T. (2011). The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. Drug Discovery Today, 16(5-6), 219-28.
van Gaal, E. V. B., Oosting, R. S., van Eijk, R., Bakowska, M., Feyen, D., Kok, R. J., Hennink, W. E., Crommelin, D. J. A., & Mastrobattista, E. (2011). DNA nuclear targeting sequences for non-viral gene delivery. Pharmaceutical Research, 28(7), 1707-22.
Dendooven, A., Ishola, D. A., Nguyen, T. Q., van der Giezen, D. M., Kok, R. J., Goldschmeding, R., & Joles, J. A. (2011). Oxidative stress in obstructive nephropathy. International Journal of Experimental Pathology, 92(3), 202-210. http://www.ncbi.nlm.nih.gov/pubmed/20804541
Altintas, I., Schiffelers, R. M., & Kok, R. J. (2011). Targeted delivery of kinase inhibitors: a nanomedicine approach for improved selectivity in cancer. Current Signal Transduction Therapy, 6, 267-278.
Haselberg, R., Harmsen, S., Dolman, M. E. M., de Jong, G. J., Kok, R. J., & Somsen, G. W. (2011). Characterization of drug-lysozyme conjugates by sheathless capillary electrophoresis-time-of-flight mass spectrometry. Analytica Chimica Acta, 698, 77-83.
D'Aurizio, E., Sozio, P., Cerasa, L. S., Vacca, M., Brunetti, L., Orlando, G., Chiavaroli, A., Kok, R. J., Hennink, W. E., & Di Stefano, A. (2011). Biodegradable microspheres loaded with an antiparkinson prodrug: an in vivo pharmacokinetic study. Molecular Pharmaceutics, 8, 2408-2415.
2010
Scholarly publications
Moreno, M., Gonzalo, T., Kok, R. J., Sancho-Bru, P., van Beuge, M., Swart, J., Prakash, J., Temming, K., Fondevila, C., Beljaars, L., Lacombe, M., van der Hoeven, P., Arroyo, V., Poelstra, K., Brenner, D. A., Gines, P., & Bataller, R. (2010). Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology, 51(3), 942-52.
Gerritsen, K. G. F., Peters, H. P., Nguyen, T. Q., Koeners, M. P. M., Wetzels, J. F., Joles, J. A., Christensen, E. I., Verroust, P. J., Li, D., Oliver, N., Xu, L., Kok, R. J., & Goldschmeding, R. (2010). Renal proximal tubular dysfunction is a major determinant of urinary connective tissue growth factor excretion. American Journal of Physiology-Renal Physiology, 298(6), F1457-F1464. http://www.ncbi.nlm.nih.gov/pubmed/20237235
Dolman, M. E. M., Harmsen, S., Storm, G., Hennink, W. E., & Kok, R. J. (2010). Drug targeting to the kidney: Advances in the active targeting of therapeutics to proximal tubular cells. Advanced Drug Delivery Reviews, 62(14), 1344-57. https://doi.org/10.1016/j.addr.2010.10.007
Leeuwis, J. W., Nguyen, T. Q., Dendooven, A. E., Kok, R. J., & Goldschmeding, R. (2010). Targeting podocyte-associated diseases. Advanced Drug Delivery Reviews, 62(14), 1325-1336. http://www.ncbi.nlm.nih.gov/pubmed/20828590
2009
Scholarly publications
de Borst, M. H., Prakash, J., Sandovici, M., Klok, P. A., Hamming, I., Kok, R. J., Navis, G., & van Goor, H. (2009). c-Jun NH2-terminal kinase is crucially involved in renal tubulo-interstitial inflammation. Journal of Pharmacology and Experimental Therapeutics, 331, 896-905.
2008
Scholarly publications
Tarrus, M., van der Sloot, A. M., Temming, K., Lacombe, M., Opdam, F. L., Quax, W. J., Molema, G., Poelstra, K., & Kok, R. J. (2008). RGD-avidin–biotin pretargeting to αvß3 integrin enhances the proapoptotic activity of TNFa related apoptosis inducing ligand (TRAIL). Apoptosis, 13, 225-235.
Kok, R. J. (2008). Targets in Fibrotic Disorders. Pharmaceutical Research, 25, 2413-2415.
Prakash, J., de Borst, M. H., van Loenen-Weemaes, A. M., Lacombe, M., Opdam, F. L., van Goor, H., Meijer, D. F. K., Moolenaar, F., Poelstra, K., & Kok, R. J. (2008). Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis. Pharmaceutical Research, 25, 2427-2439.
https://dspace.library.uu.nl/bitstream/handle/1874/41755/2008_43.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/41755/2008_43.pdf?sequence=1
Dolman, M. E. M., Fretz, M. M., Segers, G. J. W., Lacombe, M., Prakash, J., Storm, G., Hennink, W. E., & Kok, R. J. (2008). Renal targeting of kinase inhibitors. International Journal of Pharmaceutics, 364, 249-257.
Temming, K., Fretz, M. M., & Kok, R. J. (2008). Organ- and Cell-type specific delivery of kinase inhibitors: a novel approach in de development of targeted drugs. Current Molecular Pharmacology, 1, 1-12.
Prakash, J., de Borst, M. H., Lacombe, M., Opdam, F. L., Klok, P. A., van Goor, H., Meijer, D. K., Moolenaar, F., Poelstra, K., & Kok, R. J. (2008). Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. Clinical Journal of the American Society of Nephrology, 19, 2086-2097.
Prakash, J., Poelstra, K., van Goor, H., Moolenaar, F., Meijer, D. K. F., & Kok, R. J. (2008). Novel therapeutic targets for the treatment of tubulointerstitial fibrosis. Current Signal Transduction Therapy, 3(2), 97-111.
Fretz, M. M., Dolman, M. E. M., Lacombe, M., Prakash, J., Nguyen, T. Q., Goldschmeding, R., Pato, J., Storm, G., Hennink, W. E., & Kok, R. J. (2008). Intervention in growth factor activated signaling pathways by renally targeted kinase inhibitors. Journal of Controlled Release, 132(3), 200-207.
2007
Scholarly publications
Gonzalo, T., Beljaars, L., van de Bovenkamp, M., Temming, K., van Loenen, N. M., Reker-Smit, C., Meijer, D. F. K., Lacombe, M., Opdam, F. L., Keri, G., Orfi, L., Poelstra, K., & Kok, R. J. (2007). Local inhibition of liver fibrosis by specific delivery of a platelet-derived growth factor kinase inhibitor to hepatic stellate cells. Journal of Pharmacology and Experimental Therapeutics, 321, 856-865.
de Borst, M. H., Prakash, J., Melenhorst, W. B. W. H., van den Heuvel, M. C., Kok, R. J., Navis, G., & van Goor, H. (2007). Glomerular and tubular induction of the transcription factor c-Jun in human renal disease. American Journal of Pathology, 213, 219-228.
Temming, K., & Kok, R. J. (2007). Antivascular therapies: targets beyond the vessel wall. ChemMedChem, 2, 433-435.
Temming, K., Meyer, D. L., Zabinski, R., Senter, P. D., Poelstra, K., Molema, G., & Kok, R. J. (2007). Improved efficacy of alfa v beta 3 targeted albumin conjugates by conjugation of a novel auristatin derivative. Molecular Pharmaceutics, 4, 686-694.
2006
Scholarly publications
Koning, G. A., Schiffelers, R. M., Wauben, M. H. M., Kok, R. J., Mastrobattista, E., Molema, G., Ten Hagen, T. L. M., & Storm, G. (2006). Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis and Rheumatism, 54(4), 1198-1208. https://doi.org/10.1002/art.21719
Gonzalo, T., Talman, E. G., Van De Ven, A., Temming, K., Greupink, R., Beljaars, L., Reker-Smit, C., Meijer, D. K. F., Molema, G., Poelstra, K., & Kok, R. J. (2006). Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. Journal of Controlled Release, 111(1-2), 193-203. https://doi.org/10.1016/j.jconrel.2005.12.010
Everts, M., Saini, V., Leddon, J. L., Kok, R. J., Stoff-Khalili, M., Preuss, M. A., Millican, C. L., Perkins, G., Brown, J. M., Bagaria, H., Nikles, D. E., Johnson, D. T., Zharov, V. P., & Curiel, D. T. (2006). Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Letters, 6(4), 587-591.
Temming, K., Lacombe, M., Moorlag, H. E., Asgeirsdottir, S. A., Orfi, L., Kéri, G., Poelstra, K., Molema, G., & Kok, R. J. (2006). Targeting of the VEGF-kinase inhibitor PTK787 to angiogenic vasculature using RGD-equipped albumin carrier molecules. Journal of Controlled Release, 116(2), e57. https://doi.org/10.1016/j.jconrel.2006.09.048
Temming, K., Meyer, D. L., Zabinski, R., Dijkers, E. C. F., Poelstra, K., Molema, G., & Kok, R. J. (2006). Evaluation of RGD-targeted albumin carriers for specific delivery of auristatin E to tumor blood vessels. Bioconjugate Chemistry, 17, 1383-1394.
Prakash, J., Sandovici, M., Saluja, V., Lacombe, M., Schaapveld, R. Q. J., de Borst, M. H., van Goor, H., Henning, R. H., Proost, J. H., Moolenaar, F., Keri, G., Meijer, D. F. K., Poelstra, K., & Kok, R. J. (2006). Intracellular delivery of the p38 mitogen-activated protein kinase Inhibitor SB202190 [4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole] in renal tubular Cells: a novel strategy to treat renal fibrosis. Journal of Pharmacology and Experimental Therapeutics, 319, 1-12.
https://dspace.library.uu.nl/bitstream/handle/1874/237661/2006_38.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/237661/2006_38.pdf?sequence=1
Temming, K., Lacombe, M., van der Hoeven, P., Pradash, J., Gonzalo, T., Dijkers, E. C. F., Orfi, L., Keri, G., Poelstra, K., Molema, G., & Kok, R. J. (2006). Delivery of the p38 MAPkinase inhibitor SB202190 to angiogenic endothelial cells: development of novel RGD-equipped and PEGylated drug-albumin conjugates using platinum(II)-based drug linker technology. Bioconjugate Chemistry, 17, 1246-1255.
https://dspace.library.uu.nl/bitstream/handle/1874/237660/2006_34.pdf?sequence=1
https://dspace.library.uu.nl/bitstream/handle/1874/237660/2006_34.pdf?sequence=1
Temming, K., Lacombe, M., Schaapveld, R. Q. J., Orfi, L., Kéri, L., Poelstra, K., Molema, G., & Kok, R. J. (2006). Rational Design of RGD-albumin conjugates for targeted delivery of the VEGF-R kinase inhibitor PTK787 to angiogenic endothelium. ChemMedChem, 1, 1200-1203.
2005
Scholarly publications
Prakash, J., Saluja, V., Visser, J., Moolenaar, F., Meijer, D. K. F., Poelstra, K., & Kok, R. J. (2005). Bioanalysis and pharmacokinetics of the p38 MAPkinase inhibitor SB202190 in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 826(1-2), 220-225. https://doi.org/10.1016/j.jchromb.2005.09.005
Kułdo, J. M., Westra, J., Àsgeirsdóttir, S. A., Kok, R. J., Oosterhuis, K., Rots, M. G., Schouten, J. P., Limburg, P. C., & Molema, G. (2005). Differential effects of NF-κB and p38 MAPK inhibitors and combinations thereof on TNF-α- and IL-1β-induced proinflammatory status of endothelial cells in vitro. American Journal of Physiology - Cell Physiology, 289(5 58-5). https://doi.org/10.1152/ajpcell.00620.2004
Temming, K., Schiffelers, R. M., Molema, G., & Kok, R. J. (2005). RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resistance Updates, 8(6), 381-402. https://doi.org/10.1016/j.drup.2005.10.002
Greupink, R., Bakker, H. I., Reker-Smit, C., Van Loenen-Weemaes, A-M., Kok, R-J., Meijer, D. K. F., Beljaars, L., & Poelstra, K. (2005). Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. Journal of Hepatology, 43(5), 884-892. https://doi.org/10.1016/j.jhep.2005.04.014
Kułdo, J. M., Ogawara, K. I., Werner, N., Ásgeirsdóttir, S. A., Kamps, J. A. A. M., Kok, R. J., & Molema, G. (2005). Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. Current Vascular Pharmacology, 3(1), 11-39. https://doi.org/10.2174/1570161052773898
Prakash, J., Van Loenen-Weemaes, A. M., Haas, M., Proost, J. H., Meijer, D. K. F., Moolenaar, F., Poelstra, K., & Kok, R. J. (2005). Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme. Drug Metabolism and Disposition, 33(5), 683-688. https://doi.org/10.1124/dmd.104.002808
Prakash, J., Kok, R. J., van Loenen-Weemaes, A., Haas, M., Proost, J. H., Meijer, D. K., & Moolenaar, F. (2005). Renal targeting of captopril using subcutaneous administration of captopril-lysozyme conjugate. Journal of Controlled Release, 101(1-3), 350-351.
2004
Scholarly publications
Windt, W. A. K. M., Prakash, J., Kok, R. J., Moolenaar, F., Kluppel, C. A., de Zeeuw, D., van Dokkum, R. P. E., & Henning, R. H. (2004). Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 5(4), 197-202.
Ogawara, K. I., Rots, M. G., Kok, R. J., Moorlag, H. E., Van Loenen-Weemaes, A-M., Meijer, D. K. F., Haisma, H. J., & Molema, G. (2004). A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Human Gene Therapy, 15(5), 433-443. https://doi.org/10.1089/10430340460745766
Van Zanten, J., Van Der Meer, B. D., Audouy, S., Kok, R. J., & de Leij, L. F. M. H. (2004). A nonviral carrier for targeted gene delivery to tumor cells. Cancer Gene Therapy, 11(2), 156-164. https://doi.org/10.1038/sj.cgt.7700668
Schraa, A. J., Kok, R. J., Botter, S. M., Withoff, S., Meijer, D. K. F., de Leij, L. F. M. H., & Molema, G. (2004). RGD-modified anti-CD3 antibodies redirect cytolytic capacity of cytotoxic T lymphocytes toward αvβ3-expressing endothelial cells. International Journal of Cancer, 112(2), 279-285. https://doi.org/10.1002/ijc.20413
2003
Scholarly publications
Everts, M., Koning, G. A., Kok, R. J., Ásgeirsdóttir, S. A., Vestweber, D., Meijer, D. K. F., Storm, G., & Molema, G. (2003). In vitro cellular handling and in vivo targeting of E-selectin-directed immunoconjugates and immunoliposomes used for drug delivery to inflamed endothelium. Pharmaceutical Research, 20(1), 64-72. https://doi.org/10.1023/A:1022298725165
Ásgeirsdóttir, S. A., Kok, R. J., Everts, M., Meijer, D. K. F., & Molema, G. (2003). Delivery of pharmacologically active dexamethasone into activated endothelial cells by dexamethasone-anti-E-selectin immunoconjugate. Biochemical Pharmacology, 65(10), 1729-1739. https://doi.org/10.1016/S0006-2952(03)00122-9
Janssen, A. P. C. A., Schiffelers, R. M., ten Hagen, T. L. M., Koning, G. A., Schraa, A. J., Kok, R. J., Storm, G., & Molema, G. (2003). Peptide-targeted PEG-liposomes in anti-angiogenic therapy. International Journal of Pharmaceutics, 254(1), 55-58. https://doi.org/10.1016/S0378-5173(02)00682-8
Everts, M., Ásgeirsdóttir, S. A., Kok, R. J., Twisk, J., De Vries, B., Lubberts, E., Bos, E. J., Werner, N., Meijer, D. K. F., & Molema, G. (2003). Comparison of E-selectin expression at mRNA and protein levels in murine models of inflammation. Inflammation Research, 52(12), 512-518. https://doi.org/10.1007/s00011-003-1211-7
Schiffelers, R. M., Koning, G. A., ten Hagen, T. L. M., Fens, M. H. A. M., Schraa, A. J., Janssen, A. P. C. A., Kok, R. J., Molema, G., & Storm, G. (2003). Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. Journal of Controlled Release, 91, 115-122.
2002
Scholarly publications
Schraa, A. J., Everts, M., Kok, R. J., Ásgeirsdóttir, S. A., Meijer, D. K. F., de Leij, L. F. M. H., & Molema, G. (2002). Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases. Biotechnolology Annual Review, 8, 133-165. https://doi.org/10.1016/S1387-2656(02)08007-9
Schiffelers, R. M., Molema, G., Hagen, T. L. M. T., Janssen, A. P. C. A., Schraa, A. J., Kok, R. J., Koning, G. A., & Storm, G. (2002). Ligand-targeted liposomes directed against pathological vasculature. Journal of Liposome Research, 12(1-2), 129-135. https://doi.org/10.1081/LPR-120004785
Kok, R. J., Everts, M., Ásgeirsdóttir, S. A., Meijer, D. K. F., & Molema, G. (2002). Cellular handling of a dexamethasone-anti-E-selectin immunoconjugate by activated endothelial cells: Comparison with free dexamethasone. Pharmaceutical Research, 19(11), 1730-1735. https://doi.org/10.1023/A:1020769716288
Schraa, A. J., Kok, R. J., Moorlag, H. E., Bos, E. J., Proost, J. H., Meijer, D. K. F., de Leij, L. F. M. H., & Molema, G. (2002). Targeting of RGD-modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study. International Journal of Cancer, 102(5), 469-475. https://doi.org/10.1002/ijc.10727
Schiffelers, R. M., Molema, G., Ten Hagen, T. L. M., Janssen, A. P. C. A., Schraa, A. J., Kok, R. J., Koning, G. A., & Storm, G. (2002). Targeting of liposomes to angiogenic endothelial cells. Cellular & molecular biology letters, 7(2), 255.
Schraa, A. J., Kok, R. J., Berendsen, A. D., Moorlag, H. E., Bos, E. J., Meijer, D. K. F., de Leij, L. F. M. H., & Molema, G. (2002). Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting. Journal of Controlled Release, 83(2), 241-251. https://doi.org/10.1016/S0168-3659(02)00206-7
Kok, R. J., Schraa, A. J., Bos, E. J., Moorlag, H. E., Asgeirsdóttir, S. A., Everts, M., Meijer, D. K. F., & Molema, G. (2002). Preparation and functional evaluation of RGD-modified proteins as alpha(v)beta(3) integrin directed therapeutics. Bioconjugate Chemistry, 13(1), 128-135.
de Groot, F. M. H., Broxterman, H. J., Adams, H. P. H. M., van Vliet, A., Tesser, G. I., Elderkamp, Y. W., Schraa, A. J., Kok, R. J., Molema, G., Pinedo, H. M., & Scheeren, H. W. (2002). Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug. Molecular Cancer Therapeutics, 1(11), 901-911.
Everts, M., Kok, R. J., Ásgeirsdóttir, S. A., Melgert, B. N., Moolenaar, T. J. M., Koning, G. A., van Luyn, M. J. A., Meijer, D. K. F., & Molema, G. (2002). Selective intracellular delivery of dexamethasone into activated endothelial cells using an E-selectin-directed immunoconjugate. Journal of Immunology, 168(2), 883-889.
Kok, R. J., Haverdings, R. F. G., Grijpstra, F., Koiter, J., Moolenaar, F., de Zeeuw, D., & Meijer, D. K. F. (2002). Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure. Journal of Pharmacology and Experimental Therapeutics, 301(3), 1139-1143. https://doi.org/10.1124/jpet.301.3.1139
Schiffelers, R. M., Molema, G., ten Hagen, T. L. M., Janssen, A. P. C. A., Schraa, A. J., Kok, R. J., Koning, G. A., & Storm, G. (2002). Ligand-targeted liposome directed against pathological vasculature. Journal of Liposome Research, 12, 129-135.
Professional publications
Koning, G. A., Wauben, M. H. M., ten Hagen, T. L. M., Everts, M., Kok, R. J., Schraa, A. J., Molema, G., Schiffelers, R. M., & Storm, G. (2002). Liposomes for drug targeting to endothelial cells at inflammatory sites. Endothelium : journal of endothelial cell research, 9, 129-127.
1999
Scholarly publications
Kok, R. J., Grijpstra, F., Walthuis, R. B., Moolenaar, F., de Zeeuw, D., & Meijer, D. K. F. (1999). Specific delivery of captopril to the kidney with the prodrug captopril- lysozyme. Journal of Pharmacology and Experimental Therapeutics, 288(1), 281-285.
1998
Scholarly publications
Kok, R. J., Haas, M., Moolenaar, F., de Zeeuw, D., & Meijer, D. K. F. (1998). Drug delivery to the kidneys and the bladder with the low molecular weight protein lysozyme. Renal Failure, 20(2), 211-217. https://doi.org/10.3109/08860229809045104
1997
Scholarly publications
Kok, R. J., Visser, J., Moolenaar, F., de Zeeuw, D., & Meijer, D. K. F. (1997). Bioananalysis of captopril: two sensitive high-performance liquid chromatographic method with pre- or postcolumn fluorescent labeling. Journal of Chromatography - Biomedical Applications, 693(1), 181-189. https://doi.org/10.1016/S0378-4347(97)00002-9